Mukesh Ambani, CMD, Reliance Industry Ltd, who has been leading the
Reliance Life Sciences (RLS) initaitive since 2001, will continue to drive it
post the new alignment of businesses at Reliance Group.

June 18 was a day of rejoice for over three million
shareholders of the Reliance Group. On the day Kokilaben Ambani, wife of late
Dhirubhai Ambani, founder chairman of Reliance Industries, one of the leading
business conglomerates in India with total turnover of Rs 73,164 crore for the
year ending March 31, 2005 amicably resolved the seven-month ownership feud
between her two sons Mukesh and Anil by issuing a statement. As per the
settlement formula, Mukesh got complete control over the oil refining and gas
firm Reliance Industries and the petrochemicals business Indian Petrochemicals
Corporation Ltd (IPCL). Anil, on the other hand, would manage the power utility
Reliance Energy, the finance firm Reliance Capital and telecom services major
Reliance Infocomm.

However Kokilaben' statement contained no information of
the some of the other group companies including Reliance Life Sciences Pvt Ltd,
the biotechnology venture of the Reliance Group which is still in the process of
profit making. When contacted, Reliance spokesperson confirmed that Mukesh
Ambani, chairman and managing director of Reliance Industry Ltd who has been
driving and guiding the Reliance Life Sciences since 2001, still holds the
control on the life sciences initiative of the Group.

A new beginningThe Reliance Group saw a major opportunity emerging in the field of
biotechnology in the 21st century. This motivated the creation of RLS with an
investment of $5 million in the cell biology facility in 2001 as a new
millennium initiative of the Reliance Group.

At RLS the embryonic stem cell work was started in April 2001
as per the guidelines of the Indian Council of Medical Research and the National
Institutes of Health, USA. The embryonic stem cell group is also focusing on
basic research such as gene discovery, drug discovery and establishment of
several transformed cell lines. The RLS's cell biology research activities are
being carried out at Sir Hurkishondas Nurrotumdas Hospital in Mumbai and
Reliance had pumped in Rs 100 crore for its upgradation in 1997.

Reliance Life Sciences joined hands with Thyrocare
Technologies, the world's largest thyroid testing laboratory to offer DNA
technology-based genetic testing services across the country. It has created a
comprehensive Genetic Center as part of its cell biology group. The Reliance
Group will be investing about $25 million in cell biology research that focuses
on stem cells and tissue engineering. This covers embryonic stem cells,
haematopoietic stem cells, skin cells, tissue engineering, genetics and
molecular diagnostics.

Reliance Life Sciences, a closely held company, is now in the
process of setting up its Cord Blood Repository (CBR) and plans to grow the
repository to around 30,000 units over the next two-three years. The CBR is part
of the cell biology group and has to date, collected, tested and stored the cord
blood. The stem cell-enriched CBR initiative of RLS is an investment for the
future. The RLS is expected to complete the HLA (Human Leukocyte Antigen) typing
of the blood in the next eight months and would be followed by animal testing
and matching of donor-receiver.

The RLS will soon move out of its makeshift base from the
city hospital to its own campus in Navi Mumbai, with an eye on scaling up- the
critical mass being 10,000 stem cell units before the company can join a global
network of cord blood repositories. Kvaerner, the international Engineering and
Construction Group, based in the US has already been developing the life
sciences complex for Reliance since 2002. The RLS campus, which is a fast track
project, will include R&D laboratories, a cGMP pilot plant, animal
environments and a green house. It has developed specific target oriented,
efficient screen systems-both biological as well as chemicals to aim at lead
optimization through iterative medicinal and automated synthetic methods.

Besides stem cell research, Reliance Life Sciences is
developing business opportunities in the domains of medical biotechnology, plant
biotechnology, industrial biotechnology, contract research and clinical trials.
RLS' facility at Jamnagar primarily focuses on plant biotechnology projects
where modern farming methods are being tried in arid areas. In addition to this,
Jamnagar also has facilities for carrying out industrial biotechnology research
by addressing the biopolymers, biofuels and bioprocess development
opportunities.

Reliance Life Sciences that filed about nine patents in
India, according to a study done by the Patent Facility Centre (PFC), under the
Technology Information Forecasting and Assessment Council, has been offering few
products and services in both medical and plant biotechnology space. Besides RLS
offers services in molecular diagnostics and genetic testing under RelIx brand
to institutions and doctors. But its products are still to make headway in the
market and earn profits. One has to wait and watch how this new millennium
initiative of the Reliance Group will bring cheer among its shareholders by
adding value to their shares.